Journals / Journal of Neurological Sciences (Turkish) / 2011 / Cilt: 28 - Sayı: 3

Primer Glisarkoma: Klinik ve Patolojik Değerlendirme İle Dört Vakanın Sunumu

Primary Gliosarcoma: Clinical and Pathological Evaluation of Four Cases

Pages
402–409
Publication Date
2022-10-19
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Surgical resection and RT are the mostefficient treatment procedures as in all glial tumors, with poor prognosis.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Aims and Background: Gliosarcoma is an uncommon primary malignant tumor of thecentral nervous system.
📊
Key Findings & Data:They form up to 2% of allglioblastomas, and are similar to the glioblastoma in terms of prognosis.
💡
Conclusion & Impact:Surgical resection and RT are the mostefficient treatment procedures as in all glial tumors, with poor prognosis.
🔬Design:Review & Systematic Survey
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Aims and Background: Gliosarcoma is an uncommon primary malignant tumor of thecentral nervous system. Gliosarcoma is a variant of glioblastoma, which includes glial andmesenchymal differentiation sites and has biphasic tissue patterns. They form up to 2% of allglioblastomas, and are similar to the glioblastoma in terms of prognosis. Four patientspresenting with gliosarcoma were reviewed and are discussed herein with respect to theirclinical and histopathological characteristics. The diagnosis was suspected based onradiological findings and was confirmed by histological examination.Methods: The tumors were diagnosed with neurological examination and neuroimagingmethods. There were 4 patients (3 males and 1 female; age range: 33 to 36 years). All thetumors were located in the supratentorial region. All the patients underwent surgery withcraniotomy and three of them received post-surgical radiotherapy (RT).Results: Despite the surgical resection and RT, one patient died in the early stage.Recurrences were seen in the follow-up exams between 9 13 months. All of the patients diedin the follow-up period. Pathological diagnosis of the patients was gliosarcoma. Biphasictissue pattern including gliomatosis and sarcomatosis sites, which is a typical characteristic ofgliosarcoma, was histopathologically detected.Conclusions: Gliosarcoma is also seen clinically with aggressive course and poor prognosis.These tumors are accepted as grade IV according to the World Health Organizationclassification and the recurrence rates are high. Surgical resection and RT are the mostefficient treatment procedures as in all glial tumors, with poor prognosis.

Özet

Amaç: Gliosarkoma, glial ve mezenkimal diferansiasyon alanları içeren bifazik dokupaternine sahip, glioblastomun bir varyantıdır. Santral sinir sistemi tümörlerinin nadir görülenbir türüdür. Gliosarkomlar, glioblastomların %2'sini oluşturmaktadır. Tümör prognozaçısından glioblastomaya benzerlik göstermektedir. Kliniğimizde glisarkom tanısı alan dörtvakanın klinik ve histopatolojik özellikleri tartışılmıştır.Method: Nörolojik muayene ve görüntüleme yöntemleri ile tümör tanısı kondu. Hastalardanüçü erkek biri kadın idi. Yaş aralığı 33-66 arasındaydı. Tümörlerin hepsi supratentorialyerleşimliydi. Tüm hastalara kraniotomi ile cerrahi uygulandı. Cerrahi sonrası üç hastayaradyoterapi verildi.Bulgular: Cerrahi rezeksiyon ve radyoterapiye rağmen bir hastamız erken dönemde öldü. 9- 13 aylık takipler sonrasında tümörlerin nüks ettiği görüldü. Tüm hastalarımız bu takipsüresinde kaybedildi. Histopatolojik olarak; gliosarkom için tipik olan gliomatöz vesarkomatöz alanlar içeren bifazik doku paterni tespit edildi.Sonuç: Gliosarkoma klinik olarak agresif seyirli olup oldukça kötü bir prognoza sahiptir. Butümörler WHO (World Health Organization) sınıflamasına göre grade IV kabul edilip, nüksoranı yüksektir. Tüm kötü prognozlu glial tümörler gibi cerrahi rezeksiyon ve radyoterapi eniyi tedavi yöntemidir.

🔖

Cite This Article

HASTURK, A. E., CANBAY, S., BASMACI, M., AYATA, T., COBANOGLU, M. (2022). Primer Glisarkoma: Klinik ve Patolojik Değerlendirme İle Dört Vakanın Sunumu. Journal of Neurological Sciences (Turkish), Cilt: 28 - Sayı: 3, 402–409. https://ajindex.com/articles/565346

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (13)

  1. Actor B, Cobbers JM, Buschges R, Wolter M, Knobbe CB, Lichter P, et al. Comprehensive analysis of genomic alterations in gliosarcoma and its two tissue components: Genes Chromosomes Cancer 2002; 34:416–427
  2. Beaumont T, Kupsky WJ, Barger GR, Sloan AE. Glioblastoma with multiple extracranial metastases: case report and review of literature: J Neurooncol 2007; 83:39–46
  3. Biernat W, Aguzzi A, Sure U, Grant JW, Kleihues P, Hegi ME. Identical mutations of the p53 tumor suppressor gene in the gliomatous and the sarcomatous components of gliosarcomas suggest a common origin f rom glial cells: J Neuropathol Exp Neurol 1995; 54:651–656
  4. Boerman R, Anderl K, Herath J, Borell T, Johnson N, Schaeff er-Klein J, et al. The glilal and mesenchymal elements of gliosarcomas share similar genetic alterations: J Neuropathol Exp Neurol 1996; 55:973–981
  5. Cerda-Nicolas M, Kepes J. Gliof ibromas (including malignant f orms), and gliosarcomas: a comparative study and review of literature: Acta Neuropathol 1993; 85:349–361
  6. Cervoni L, Celli P. Cerebral gliosarcoma: prognostic f actors: Neurosurg Rev 1996; 19:93–96
  7. Deb P, Sharma MC, Chander B, Mahapatra AK, Sarkar C. Giant cell glioblastoma multif orme: report of a case with prolonged survival and transf ormation to gliosarcoma: Childs Nerv Syst 2006; 22:314–319
  8. Feigin I, Gross SW. Sarcoma arising in glioblastoma of the brain: Am J Pathol 1954; 31:633–653 9. Feigin I, Allen LB, Lipkin L, Gross SW. The endothelial hyperplasia of cerebral blood vessels with brain tumors, and its sarcomatous transf ormation: Cancer 1958; 2:264–277
  9. Galanis E, Buckner JC, Dinapoli RP, Scheithauer BW, Jenkins RB, Wang CH, et al. Clinical outcome of gliosarcoma compared with glioblastoma multif orme: north central cancer treatment group results: J Neurosurg 1998; 89:425–430
  10. Grant J, Steart TV, Aguzzi A, Jones DB, Gallagher PJ. Gliosarcoma: an immunohistochemical study: Acta Neuropathol 1989; 79:305–309
  11. Han J.S, Yang I, Tihan T, Prados M.D., Parsa A.T. Primary gliosarcoma: key clinical and pathologic distinctions f rom glioblastoma with implications as a unique oncologic entity: J Neurooncol 2010; 96:313–320
  12. Kozak KR, Mahadevan A, Moody JS. Adult gliosarcoma: epidemiology, natural history, and f actors associated with outcome: Neuro-Oncology 2009; 11(2):183-191
  13. Louis D, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, et al. The 2007 WHO classif ication of tumours of the central nervous system: Acta Ne